Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
409 stopped studies mapped to Mature B-Cell Non-Hodgkin Lymphoma and descendants · 88% state a reason
Over the 409 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients… | Phase 1 / Phase 2 | suspended | May 16, 2023 | City of Hope Medical Center | Safety Issues | Safety / toxicity |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in… | Phase 1 / Phase 2 | suspended | Aug 1, 2025 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT05660395 | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in… | Phase 1 | terminated | Dec 21, 2022 | ADC Therapeutics S.A. | This decision to close the study was made following interactions with regulatory authorities and in… | Safety / toxicity |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Phase 1 | terminated | Apr 25, 2023 | BeOne Medicines | This decision is due to a company business decision with strategy change on the BGB-21447… | Safety / toxicity |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse…(EPCORE DLBCL-3) | Phase 2 | terminated | Dec 21, 2022 | Genmab | The study was terminated because sufficient data had been collected to meet the objectives of the… | Safety / toxicity |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Phase 2 | terminated | Jul 12, 2022 | University of Washington | The trial closed early due to slow accrual. | Enrollment / accrual |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With… | Phase 2 | terminated | Aug 27, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study sponsor withdrew funding early, forcing this study to stop all activity and close… | Funding |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | Phase 1 / Phase 2 | terminated | Apr 1, 2021 | Genmab | The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review… | Sponsor / business decision |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And…(MAPtivate-6) | Phase 1 / Phase 2 | terminated | Jun 9, 2023 | Pfizer | Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not… | Safety / toxicity |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory… | Phase 2 | terminated | Apr 24, 2018 | Mayo Clinic | Discontinued after interim analysis for futility; no treatment successes observed in the first 12… | Efficacy / futility |
| NCT07282548 | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least… | — | withdrawn | Dec 15, 2025 | Ipsen | Withdrawn prior to enrolment after review of updated safety data | Safety / toxicity |
| NCT06125028 | [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma(LYMFOR) | Phase 3 | terminated | Nov 9, 2023 | Pentixapharm AG | low recruitment rate | Enrollment / accrual |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | terminated | Aug 11, 2022 | UNC Lineberger Comprehensive Cancer Center | Funding | Funding |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 | terminated | Nov 16, 2022 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in… | Phase 3 | withdrawn | Mar 15, 2024 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Replaced with another clinical trial. | Other (stated, no rule matched) |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell… | Phase 1 | terminated | Jun 6, 2018 | MEI Pharma, Inc. | Business reasons, not related to safety or efficacy results. | Safety / toxicity |
| NCT04676360 | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | Phase 2 | terminated | Dec 21, 2020 | Jacob Soumerai, MD | The study was closed given lack of efficacy and plans to publish this negative study. | Efficacy / futility |
| NCT03919175 | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and… | Phase 2 | terminated | Apr 18, 2019 | Massachusetts General Hospital | Umbralisib development terminated; closed to accrual 8/29/2022 | Enrollment / accrual |
| NCT04205838 | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy… | Phase 2 | terminated | Dec 20, 2019 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT04268277 | Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY | Phase 2 | terminated | Feb 13, 2020 | University of Ulm | Due to slow recruitment caused by the COVID-19 pandemic and associated retrictions and the… | COVID-19 / pandemic |
| NCT03990961 | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | terminated | Jun 19, 2019 | University of Chicago | Study was closed early due to slow enrollment. | Enrollment / accrual |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Feb 26, 2020 | Rutgers, The State University of New Jersey | This study was never submitted to the IRB for review and approval. No research subjects were… | Enrollment / accrual |
| NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With…(Mandolin) | Phase 2 | withdrawn | Oct 5, 2023 | Epizyme, Inc. | Never started | Other (stated, no rule matched) |
| NCT06575686 | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa… | Phase 2 | suspended | Aug 28, 2024 | City of Hope Medical Center | Pending Interim Analysis | Efficacy / futility |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | Phase 1 / Phase 2 | suspended | Apr 22, 2021 | Masonic Cancer Center, University of Minnesota | Accrual met | Enrollment / accrual |
| NCT04230304 | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | terminated | Jan 18, 2020 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT06106841 | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | terminated | Oct 30, 2023 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Study terminated for strategic business reasons | Sponsor / business decision |
| NCT05179603 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Jan 5, 2022 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic… | Phase 1 / Phase 2 | terminated | Apr 8, 2022 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03498612 | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Phase 2 | terminated | Apr 13, 2018 | University of Washington | Closed per SRC Low Accrual Policy. | Enrollment / accrual |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive…(UPCC 25406) | Phase 1 / Phase 2 | terminated | Oct 21, 2008 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT05169489 | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1 | terminated | Dec 27, 2021 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With… | Phase 1 / Phase 2 | terminated | Nov 23, 2022 | Pfizer | The trial terminated due to the inability to recruit the planned number of subjects. The decision… | Safety / toxicity |
| NCT01198067 | Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom… | Phase 1 | terminated | Sep 9, 2010 | M.D. Anderson Cancer Center | \<75% participant accrual | Enrollment / accrual |
| NCT05490043 | A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell… | Phase 1 | terminated | Aug 5, 2022 | Antengene (Hangzhou) Biologics Co., Ltd. | The sponsor has decided to adjust the development strategy of the investigational drug in this… | Sponsor / business decision |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Phase 1 | terminated | Sep 14, 2016 | Novartis Pharmaceuticals | The decision of early termination was made due to business reasons, and was not based on any safety… | Safety / toxicity |
| NCT04433182 | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large… | Phase 2 | terminated | Jun 16, 2020 | Fondazione Italiana Linfomi - ETS | low enrollment rate | Enrollment / accrual |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of… | Phase 1 | terminated | Apr 2, 2024 | Roswell Park Cancer Institute | Manufacturing issues | Drug supply |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+…(NAVAL-1) | Phase 2 | terminated | Aug 18, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT03401853 | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or… | Phase 2 | terminated | Jan 17, 2018 | University of Washington | Study terminated to end of funding. | Funding |
| NCT03287817 | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment…(ALEXANDER) | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Autolus Limited | After reviewing the data and taking into consideration the available treatment landscape in r/r… | Other (stated, no rule matched) |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT05121103 | A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative… | Phase 1 | terminated | Nov 16, 2021 | Epizyme, Inc. | Strategic business decision | Sponsor / business decision |
| NCT04735471 | A Phase 1 Study of ADI-001 in B Cell Malignancies(GLEAN-1) | Phase 1 | terminated | Feb 3, 2021 | Adicet Therapeutics | Terminated - Halted Prematurely | Other (stated, no rule matched) |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel… | N/A | withdrawn | Nov 3, 2021 | Case Comprehensive Cancer Center | Study closed prior to enrollment of first participant | Enrollment / accrual |
| NCT04986865 | A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell…(PROBE) | Phase 1 | terminated | Aug 3, 2021 | Antengene Biologics Limited | It is due to the recent changes in the competitor landscape and strategic consideration | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials